ClinicalTrials.gov
public full text
Public Domain
Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
This study will determine the maximum tolerated dose of genetically modified natural killer (NK) cells in research participants with relapsed or refractory B-lineage acute lymphoblastic leukemia (ALL).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Treatment of Malignant Tumors With NK Cell#888085
- Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia#303741
- Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG#1214685
- Natural Killer Cells in Older Patients With Acute Myeloid Leukemia#825606
- Haploidentical NK-cell Infusion in Acute Myeloid Leukemia#851022
Record · ID 1321992
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive